Sotac Pharmaceuticals Limited (NSE:SOTAC)

Market Cap	1.38B +2.5%
Revenue (ttm)	846.72M -19.3%
Net Income	85.60M +91.9%
EPS	7.74 +91.8%
Shares Out	11.05M
PE Ratio	16.15
Forward PE	n/a
Dividend	0.10 (0.08%)
Ex-Dividend Date	Sep 19, 2025

Volume	1,200
Average Volume	3,000
Open	125.00
Previous Close	124.20
Day's Range	125.00 - 125.00
52-Week Range	88.05 - 152.35
Beta	-0.18
RSI	55.02
Earnings Date	Feb 4, 2026

About Sotac Pharmaceuticals

Sotac Pharmaceuticals Limited engages in the production, manufacturing, processing, and sale of various pharmaceutical products in India. Its therapeutic product portfolio includes anti-diabetic, anti-psychotic, vitamins, minerals, iron supplements, anti-cold, anti-allergic, dermatological solutions, antacid, anti-ulcerants, PPI, anti-emetics, cardiac, anti-hypertensives, analgesic, anti-pyretic, anti-inflammatory, anti-bacterial, anti-viral, general antibiotics, IP-lactams and non-IP-lactams, anti-fungal, and cephalosporin products. The compan...

• Industry: Pharmaceutical Preparations
• Founded: 2014
• Employees: 127
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SOTAC

Financial Performance

In fiscal year 2025, Sotac Pharmaceuticals's revenue was 1.00 billion, a decrease of -3.57% compared to the previous year's 1.04 billion. Earnings were 80.27 million, an increase of 87.48%.